Menu ×

HEALTHCARE & PHARMACEUTICAL

Renal Disease Treatment Market Segmentation By Disease (Acute Kidney Failure, Chronic Kidney Disease [CKD], End-Stage Renal Disease [ESRD] and Others); By Treatment (Drugs, Surgery, Dialysis, Kidney Transplant and Others); By End User (Hospitals, Clinics, Dialysis Centers, Home Care and Others) – Global Demand Analysis & Opportunity Outlook 2027

  • Text Size:

Extensive insights into the Growth of Renal Disease Treatment Market amidst COVID-19

Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.

Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.

We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.

In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months.                                                         Request Insights

Read More
IN THE NEWS

On June 6, 2019, Novartis announced that the new early stage histology data in kidney transplantation, presented at the American Transplant Congress (ATC), suggested that the monoclonal antibody compound iscalimab (CFZ533) might be able to extend the durability of transplanted kidneys and improve the long-term outcomes for the patients after kidney transplantation procedures.

Renal Disease Treatment Market Overview

Renal diseases are disorders of the kidney which affect the process of filtration of the blood, thereby requiring external aid such as dialysis in order to perform its function. The main kidney disorders include chronic kidney disease, acute kidney failure, kidney stones, glomerulonephritis and end-stage renal disease. Effective and improved treatment methods are required so as to reduce the effects of the disease on the body and recover the damage done to the kidneys. This is leading to a high demand for such therapies and treatment methods, thereby resulting in a high potential for the market growth.

Market Size and Forecast

The renal disease treatment market is anticipated to record a CAGR of around 6.5% over the forecast period, i.e., 2019-2027. The market is segmented by disease, by treatment, by end user and by region, out of which, the disease segment is further segmented into acute kidney failure, chronic kidney disease [CKD], end-stage renal disease [ESRD] and others. Based on disease, the chronic kidney disease (CKD) segment is anticipated to hold the largest share in the renal disease treatment market. As per a 2019 report published by the Centers for Disease Control and Prevention, around 15% of adults living in the United States, which means about 37 million people, are estimated to have chronic kidney disease (CKD). Out of these, the current estimates suggest that the disease is not diagnosed in 9 in every 10 people living with CKD. Moreover, according to the current estimates, the prevalence of CKD is higher among the older population, i.e., people who are aged 65 years or more with 38% prevalence. For adults aged between 45 to 64 years, the incidence of this disorder is anticipated to be 13% while for adults aged between 18 and 44 years, it is 7%. Furthermore, the report states that chronic kidney disease is more common in women than men with 15% and 12% prevalence respectively. The higher cases of chronic kidney disease among the population is estimated to result in the growth of this segment over the forecast period. CLICK TO DOWNLOAD SAMPLE REPORT 

Renal-Disease-Treatment-Market-Growth

Growth Drivers

Rising Expenditure on Medical Treatments to Boost the Growth of Industry

The spending on healthcare is increasing globally on account of high demand for improved medical devices, treatments and services which result in development of better and costlier technology. The willingness of people to spend more in this industry in order to receive quality treatment is another attributable factor for the increase in healthcare expenditure. The World Health Organization presented statistics on health expenditure which stated that around 10.02% of the world’s GDP comprised of healthcare expenditure in 2016. In the United States, the healthcare expenditure was noted to be 17.07% of the GDP, while it was around 11.13% and 10.92% in Germany and Japan respectively. The growing healthcare expenditure by people belonging to various nations across the world is anticipated to become another growth stimulating factor for the market.

Growing Incidences of Disorders Affecting the Kidney to Support the Market Growth

The changing lifestyles of people leading to unhealthy food habits and poor health results in development of various disorders. The increasing prevalence of health disorders that have a direct impact on the kidney, such as diabetes, hypertension and obesity are estimated to result in the growth of renal disease treatment market.

Restraints

Stringent Government Policies Regarding Approval of Treatment Methods to Restrict the Market Growth

The various medical devices and equipment developed for the treatment of renal disorders have to go through strict approval procedures which might be a lengthy and time-consuming process. Similarly, the drugs are required to go through various clinical trials before being approved for the market. The stringent government policies for the approval of treatment methods for renal disorders is estimated to become a limiting factor for the market growth.

Market Segmentation

Our in-depth analysis of the renal disease treatment market includes the following segments:

By Disease

  • Acute Kidney Failure
  • Chronic Kidney Disease [CKD]
  • End-Stage Renal Disease [ESRD]
  • Others

By Treatment

  • Drugs
  • Surgery
  • Dialysis
  • Kidney Transplant
  • Others

By End User

  • Hospitals
  • Clinics
  • Dialysis Centers
  • Home Care
  • Others

By Region

On the basis of regional analysis, the renal disease treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region.

On the basis of geography, the largest share in the renal disease treatment market is anticipated to be held by the market in North America. This can be attributed to the large patient population on account of rising adoption of unhealthy lifestyles in the region which affect the kidney and result in kidney disorders among them. Moreover, the growing expenditure on healthcare by people in North America region along with the rising demand for improved healthcare services and advanced treatments are additional factors anticipated to contribute towards the market growth. Further, the market in Europe is estimated to witness considerable growth in the upcoming years as well. The growing healthcare infrastructure in the region along with rising research and development activities in the medical industry in this region are the factors anticipated to result in the market growth. However, the highest growth rate during the forecast period is estimated to be observed by the market in Asia-Pacific. Rising awareness about renal diseases and related disorders in the region, mainly in countries such as China, Japan and India, is the foremost growth driving factor. Other factors supporting the market growth include growing healthcare expenditure, expanding healthcare infrastructure and escalating population with health disorders in the region.

The renal disease treatment market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC,  Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis.
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis

Top Featured Companies Dominating the Market

  • Novartis AG
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis
  • Abbott
  • Amgen Inc.
  • Baxter
  • Keryx Biopharamceuticals, Inc.
  • Pfizer
  • Fresenius Medical Care
  • Otsuka America Pharmaceutical, Inc.
  • Veloxis Pharmaceuticals, Inc.
  • Affymax Inc.

Related Reports


Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2020 Research Nester. All Rights Reserved